TNSN00125A1 - Des composes de formule generale - Google Patents

Des composes de formule generale

Info

Publication number
TNSN00125A1
TNSN00125A1 TNTNSN00125A TNSN00125A TNSN00125A1 TN SN00125 A1 TNSN00125 A1 TN SN00125A1 TN TNSN00125 A TNTNSN00125 A TN TNSN00125A TN SN00125 A TNSN00125 A TN SN00125A TN SN00125 A1 TNSN00125 A1 TN SN00125A1
Authority
TN
Tunisia
Prior art keywords
neurodegenerescence
compounds
general formula
diseases
disease
Prior art date
Application number
TNTNSN00125A
Other languages
English (en)
Inventor
Heitz Neidhart Marie-Paule
Jaeschke Georg
Buttelmann Bernd
Pinard Emmanuel
Wyler Rene
Alanine Alexander
Burner Serge
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of TNSN00125A1 publication Critical patent/TNSN00125A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L’INVENTION CONCERNE DES COMPOSES DE FORMULE GENERALE I : DANS LAQUELLE R1 REPRESENTE UN ATOME D’HYDROGENE OU UN GROUPE HYDROXY ; R2 REPRESENTE UN ATOME D’HYDROGENE OU UN GROUPE METHYLE ; ET X REPRESENTE –O- OU –CH2- ; ET LEURS SELS D’ADDITION D’ACIDES PHARMACEUTIQUEMENT ACCEPTABLES. IL A ETE DEMONTRE QUE CES POSSEDENT UNE BONNE AFFINITE POUR LE RECEPTEUR DE NMDA ET QUE PAR CONSEQUENT ILS SONT UTILES DANS LE TRAITEMENT DE MALADIES OU LES INDICATIONS THERAPEUTIQUES ENGLOBENT LES FORMES AIGUES DE NEURODEGENERESCENCE PROVOQUEES PAR EXEMPLE, PAR LES ATTAQUES OU LES LESIONS CEREBRALES ; LES FORMES CHRONIQUES DE NEURODEGENERESCENCE TELLES QUE LA MALADIE D’ALZHEIMER, LA MALADIE DE PARKINSON, LA CHOREE DE HUNTINGTON OU L’ALS (SCLEROSE LATERALE AMYOTROPHIQUE) ; LA NEURODEGENERESCENCE ASSOCIEE AUX INFECTIONS BACTERIENNES OU VIRALES, ET LES MALADIES TELLES QUE LA SCHIZOPHRENIE, L’ANXIETE, LA DEPRESSION ET LES DOULEURS CHRONIQUES/AIGUES.
TNTNSN00125A 1999-06-08 2000-06-03 Des composes de formule generale TNSN00125A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99111126 1999-06-08

Publications (1)

Publication Number Publication Date
TNSN00125A1 true TNSN00125A1 (fr) 2005-11-10

Family

ID=8238316

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN00125A TNSN00125A1 (fr) 1999-06-08 2000-06-03 Des composes de formule generale

Country Status (38)

Country Link
US (1) US6310213B1 (fr)
EP (1) EP1189886B1 (fr)
JP (1) JP3645856B2 (fr)
KR (1) KR100571162B1 (fr)
CN (1) CN1142141C (fr)
AR (1) AR024282A1 (fr)
AT (1) ATE315025T1 (fr)
AU (1) AU770787B2 (fr)
BR (1) BR0011419A (fr)
CA (1) CA2376091C (fr)
CO (1) CO5160328A1 (fr)
CZ (1) CZ299483B6 (fr)
DE (1) DE60025348T2 (fr)
DK (1) DK1189886T3 (fr)
EG (1) EG26101A (fr)
ES (1) ES2254183T3 (fr)
GC (1) GC0000256A (fr)
GT (1) GT200000089A (fr)
HK (1) HK1046412B (fr)
HR (1) HRP20010885B1 (fr)
HU (1) HU228591B1 (fr)
IL (2) IL146750A0 (fr)
JO (1) JO2260B1 (fr)
MA (1) MA26797A1 (fr)
MX (1) MXPA01012585A (fr)
MY (1) MY128818A (fr)
NO (1) NO320613B1 (fr)
PA (1) PA8496601A1 (fr)
PE (1) PE20010218A1 (fr)
PL (1) PL196053B1 (fr)
RS (1) RS50033B (fr)
RU (1) RU2242464C2 (fr)
SI (1) SI1189886T1 (fr)
TN (1) TNSN00125A1 (fr)
TR (1) TR200103532T2 (fr)
TW (1) TWI254043B (fr)
WO (1) WO2000075109A1 (fr)
ZA (1) ZA200109706B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE273953T1 (de) * 2000-03-22 2004-09-15 Hoffmann La Roche Piperidin- und pirazinverbindungen zur verwendung in der behandlung von alzheimer
ES2225553T3 (es) 2000-04-20 2005-03-16 F. Hoffmann-La Roche Ag Derivados de pirrolidina y piperidina y su empleo para el tratamiento de trastornos neurodegenerativos.
US6407235B1 (en) 2000-08-21 2002-06-18 Hoffmann-La Roche Inc. Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol
EP1332363A4 (fr) * 2000-10-09 2007-08-29 Kay Double Methode de detection de troubles neurodegeneratifs
US6951875B2 (en) * 2001-10-29 2005-10-04 Hoffmann-La Roche Inc. Conjugated aromatic compounds with a pyridine substituent
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
WO2009118187A1 (fr) * 2008-03-27 2009-10-01 Evotec Neurosciences Gmbh Procédés pour traiter des troubles utilisant un antagoniste sélectif de sous-type nr2b de nmda
US20150045556A1 (en) * 2011-07-18 2015-02-12 Roland E. Dolle Processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4410822A1 (de) * 1994-03-24 1995-09-28 Schering Ag Neue Piperidin-Derivate
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives

Also Published As

Publication number Publication date
PL352723A1 (en) 2003-09-08
TWI254043B (en) 2006-05-01
IL146750A (en) 2006-12-10
DE60025348T2 (de) 2006-08-24
WO2000075109A1 (fr) 2000-12-14
PA8496601A1 (es) 2001-12-14
MA26797A1 (fr) 2004-12-20
BR0011419A (pt) 2002-02-26
NO20015920D0 (no) 2001-12-04
ZA200109706B (en) 2003-02-26
EP1189886B1 (fr) 2006-01-04
RU2242464C2 (ru) 2004-12-20
HK1046412B (zh) 2004-07-09
GC0000256A (en) 2006-11-01
EP1189886A1 (fr) 2002-03-27
HK1046412A1 (en) 2003-01-10
EG26101A (en) 2013-02-17
MY128818A (en) 2007-02-28
MXPA01012585A (es) 2002-04-10
AR024282A1 (es) 2002-09-25
CZ299483B6 (cs) 2008-08-13
HUP0201916A2 (en) 2002-10-28
YU86501A (sh) 2004-09-03
CO5160328A1 (es) 2002-05-30
CN1142141C (zh) 2004-03-17
ES2254183T3 (es) 2006-06-16
RS50033B (sr) 2008-11-28
AU770787B2 (en) 2004-03-04
DE60025348D1 (de) 2006-03-30
JP3645856B2 (ja) 2005-05-11
DK1189886T3 (da) 2006-05-15
AU5218100A (en) 2000-12-28
HU228591B1 (hu) 2013-04-29
ATE315025T1 (de) 2006-02-15
HRP20010885A2 (en) 2004-02-29
IL146750A0 (en) 2002-07-25
SI1189886T1 (sl) 2006-04-30
NO320613B1 (no) 2005-12-27
NO20015920L (no) 2001-12-04
HRP20010885B1 (en) 2010-07-31
GT200000089A (es) 2001-11-29
JO2260B1 (en) 2004-10-07
JP2003501415A (ja) 2003-01-14
CA2376091C (fr) 2006-03-14
US6310213B1 (en) 2001-10-30
CN1354745A (zh) 2002-06-19
CA2376091A1 (fr) 2000-12-14
CZ20014349A3 (cs) 2002-05-15
KR20020008850A (ko) 2002-01-31
PL196053B1 (pl) 2007-11-30
KR100571162B1 (ko) 2006-04-17
TR200103532T2 (tr) 2002-05-21
HUP0201916A3 (en) 2003-05-28
PE20010218A1 (es) 2001-02-28

Similar Documents

Publication Publication Date Title
TN2009000331A1 (fr) Derives de 3-amino-pyrrolo [3,4-c]pyrazole -5- (1h,4h,6h) carbaldehyde servant d'inhibiteurs de pkc
TNSN05104A1 (fr) Derives de thiazole pour le traitement de troubles neurodegeneratifs
TNSN04224A1 (fr) (imidazol-1 yl - methyl) pyridazine en tant qu'antagoniste du recepteur pour le nmda
MA27569A1 (fr) Derives de pyrrolo-pyrazole substitues servant d'inhibiteurs de kinases
MA27781A1 (fr) 3-fluoro-piperidines comme antagonistes de nmda/nr2b.
TNSN04246A1 (fr) Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation
MA27568A1 (fr) Derives de pyrrolopyrimidine
MA27881A1 (fr) Derives d'imidazole utilises comme antagonistes du recepteur du glutamate
NZ527123A (en) Oxazolyl-pyrazole derivatives as kinase inhibitors
BR0206955A (pt) Ligantes de receptores de canabinóides
TNSN98084A1 (fr) Derives de macrolides substitues en position c-4
YU33203A (sh) Radioaktivna farmaceutska sredstva za dijagnostikovanje alchajmerove bolesti
MA30420B1 (fr) Derives de terphenyle pour le traitment de la maladie d'alzheimer
TNSN03140A1 (fr) Derives d'acides sulfoniques nouveaux.
TNSN00125A1 (fr) Des composes de formule generale
WO2001081309A3 (fr) 4-benzyl-1-[2-(4-hydroxy-phenoxy)-ethyl]-piperidine-3,4-diol
MA27197A1 (fr) Sels de tolterodine
YU86701A (sh) Jedinjenja i formulacije za inhibiciju agregacije proteina i snimanje amiloidnih naslaga
TNSN99080A1 (fr) Composes azapolycycliques condenses a noyau aryle, procede pour leur preparation et compositions pharmaceutiques les contenant
MA29793B1 (fr) Derives d'imidazole pour le traitement de troubles neurologiques.
TNSN05074A1 (fr) Piperazines heterocycliques substituees pour le traitement de la schizophrenie
BR9607443A (pt) Composto de 4-aminotetraidrobenzisoxazol ou-isatiazol composição farmacêutica e utilização do composto
TNSN96051A1 (fr) Benzamides pour le traitement de degenerescences neurologiques
MA30567B1 (fr) Dérivés d'acide phénylacétique.
TH60812A (th) อนุพันธ์อีเธนซัลโฟนิล-พิเพอริดีน